Targeting cyclic nucleotide phosphodiesterase in the heart: Therapeutic implications

Journal of Cardiovascular Translational Research

Volumn 3, Issue 5, 2010, Pages 507-515

  Miller, Clint L ^a   Yan, Chen ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Cyclic Nucleotide; Heart; Phosphodiesterase

Indexed keywords

3 ISOBUTYL 8 METHOXYMETHYL 1 METHYLXANTHINE; 9 (2 HYDROXY 3 NONYL)ADENINE; 9 (6 PHENYL 2 OXOHEX 3 YL) 2 (3,4 DIMETHOXYBENZYL)PURIN 6 ONE; BAY 607550; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 2; ENOXIMONE; IC 86340; ISOBUTYLMETHYLXANTHINE; MILRINONE; PHOSPHODIESTERASE; PHOSPHODIESTERASE I INHIBITOR; PHOSPHODIESTERASE II INHIBITOR; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PHOSPHODIESTERASE VIII; ROLIPRAM; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG; VALSARTAN; VARDENAFIL;

ADJUVANT THERAPY; ASTHMA; CARDIOGENIC SHOCK; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DIASTOLIC HEART FAILURE; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG SCREENING; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME REGULATION; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART HYPERTROPHY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEART VENTRICLE TACHYCARDIA; HUMAN; HYDROLYSIS; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; SUDDEN DEATH; SYSTOLIC DYSFUNCTION;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HUMANS; ISOENZYMES; MOLECULAR TARGETED THERAPY; MYOCARDIUM; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; SECOND MESSENGER SYSTEMS; TRANSLATIONAL RESEARCH;

ANIMALIA;

EID: 77958095148     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-010-9203-9     Document Type: Review

References (88)

1. AT Bender JA Beavo 2006 Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use Pharmacological Reviews 58 488 520 10.1124/pr.58.3.5 16968949 1:CAS:528:DC%2BD28XhtVOhtLfI (Pubitemid 44394910)
2. MA Movsesian R Alharethi 2002 Inhibitors of cyclic nucleotide phosphodiesterase PDE3 as adjunct therapy for dilated cardiomyopathy Expert Opinion on Investigational Drugs 11 1529 1536 10.1517/13543784.11.11.1529 12437500 (Pubitemid 35331487)
3. BE Jaski MA Fifer RF Wright E Braunwald WS Colucci 1985 Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside Journal of Clinical Investigation 75 643 649 10.1172/JCI111742 3973022 1:STN:280:DyaL2M7jtFOksw%3D%3D
4. Galie, N., Rubin, L. J., & Simonneau, G. (2010). Phosphodiesterase inhibitors for pulmonary hypertension. The New England Journal of Medicine, 362, 559-560, author reply 560.
5. HA Ghofrani IH Osterloh F Grimminger 2006 Sildenafil: From angina to erectile dysfunction to pulmonary hypertension and beyond Nature Reviews. Drug Discovery 5 689 702 10.1038/nrd2030 16883306 1:CAS:528:DC%2BD28XnsFCkuro%3D (Pubitemid 44151606)
6. P Kumar GS Francis WH Tang 2009 Phosphodiesterase 5 inhibition in heart failure: Mechanisms and clinical implications Nature Reviews Cardiology 6 349 355 10.1038/nrcardio.2009.32 19377497 1:CAS:528:DC%2BD1MXks12ht7w%3D
7. RC Kukreja F Salloum A Das R Ockaili C Yin YA Bremer, et al. 2005 Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications Vascular Pharmacology 42 219 232 10.1016/j.vph.2005.02.010 15922255 1:CAS:528:DC%2BD2MXks1ajtL0%3D (Pubitemid 40726325)
8. WK Sonnenburg D Seger JA Beavo 1993 Molecular cloning of a cDNA encoding the "61-kDa" calmodulin-stimulated cyclic nucleotide phosphodiesterase. Tissue-specific expression of structurally related isoforms The Journal of Biological Chemistry 268 645 652 7678006 1:CAS:528: DyaK3sXks1Kns70%3D
9. C Yan D Kim T Aizawa BC Berk 2003 Functional interplay between angiotensin II and nitric oxide: Cyclic GMP as a key mediator Arteriosclerosis, Thrombosis, and Vascular Biology 23 26 36 10.1161/01.ATV.0000046231.17365.9D 12524221 1:CAS:528:DC%2BD3sXhvF0%3D (Pubitemid 36091622)
10. 2+/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival Circulation Research 98 777 784 10.1161/01.RES.0000215576.27615.fd 16514069 1:CAS:528:DC%2BD28XislCltr8%3D
11. AT Bender JA Beavo 2006 PDE1B2 regulates cGMP and a subset of the phenotypic characteristics acquired upon macrophage differentiation from a monocyte Proceedings of the National Academy of Sciences of the United States of America 103 460 465 10.1073/pnas.0509972102 16407168 1:CAS:528: DC%2BD28XpsVSksA%3D%3D (Pubitemid 43122423)
12. 2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy Circulation Research 105 956 964 10.1161/CIRCRESAHA.109.198515 19797176 1:CAS:528:DC%2BD1MXhtlKrtrfM
13. SD Rybalkin I Rybalkina JA Beavo KE Bornfeldt 2002 Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation Circulation Research 90 151 157 10.1161/hh0202.104108 11834707 1:CAS:528:DC%2BD38XhtlyjsrY%3D (Pubitemid 34627083)
14. P Han J Werber M Surana N Fleischer T Michaeli 1999 The calcium/calmodulin-dependent phosphodiesterase PDE1C down-regulates glucose-induced insulin secretion The Journal of Biological Chemistry 274 22337 22344 10.1074/jbc.274.32.22337 10428803 1:CAS:528:DyaK1MXlt1Cgu7c%3D (Pubitemid 29379268)
15. TR Dunkern A Hatzelmann 2007 Characterization of inhibitors of phosphodiesterase 1C on a human cellular system The FEBS Journal 274 4812 4824 10.1111/j.1742-4658.2007.06001.x 17697115 1:CAS:528:DC%2BD2sXhtVyksLvM (Pubitemid 47353125)
16. RM Wallis JD Corbin SH Francis P Ellis 1999 Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro The American Journal of Cardiology 83 3C 12C 10.1016/S0002-9149(99)00042-9 10078537 1:CAS:528:DyaK1MXitFWnt7k%3D
17. F Vandeput SL Wolda J Krall R Hambleton L Uher KN McCaw, et al. 2007 Cyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes The Journal of Biological Chemistry 282 32749 32757 10.1074/jbc.M703173200 17726023 1:CAS:528:DC%2BD2sXht1CltbbN (Pubitemid 350159317)
18. K Loughney TJ Martins EA Harris K Sadhu JB Hicks WK Sonnenburg, et al. 1996 Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3′,5′-cyclic nucleotide phosphodiesterases The Journal of Biological Chemistry 271 796 806 10.1074/jbc.271.2.796 8557689 1:CAS:528:DyaK28XksFOitg%3D%3D (Pubitemid 26034930)
19. JC Clapham AF Wilderspin 2001 Cloning of dog heart PDE1A-A first detailed characterization at the molecular level in this species Gene 268 165 171 10.1016/S0378-1119(01)00413-9 11368912 1:CAS:528:DC%2BD3MXjsFWrs7s%3D (Pubitemid 32463800)
20. N Yanaka Y Kurosawa K Minami E Kawai K Omori 2003 cGMP-phosphodiesterase activity is up-regulated in response to pressure overload of rat ventricles Bioscience, Biotechnology, and Biochemistry 67 973 979 10.1271/bbb.67.973 12834273 1:CAS:528:DC%2BD3sXktlygtLg%3D
21. DC Bode JR Kanter LL Brunton 1991 Cellular distribution of phosphodiesterase isoforms in rat cardiac tissue Circulation Research 68 1070 1079 1849058 1:CAS:528:DyaK3MXitVChsro%3D
22. R Lukowski SD Rybalkin F Loga V Leiss JA Beavo F Hofmann 2010 Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes Proceedings of the National Academy of Sciences of the United States of America 107 5646 5651 10.1073/pnas.1001360107 20212138
23. E Patrucco MS Albergine LF Santana JA Beavo 2010 Phosphodiesterase 8A (PDE8A) regulates excitation-contraction coupling in ventricular myocytes Journal of Molecular and Cell Cardiology 49 330 333 10.1016/j.yjmcc.2010.03.016 1:CAS:528:DC%2BC3cXntlamsbs%3D
24. RT Schermuly SS Pullamsetti G Kwapiszewska R Dumitrascu X Tian N Weissmann, et al. 2007 Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: Target for reverse-remodeling therapy Circulation 115 2331 2339 10.1161/CIRCULATIONAHA.106.676809 17438150 1:CAS:528:DC%2BD2sXksFSjtrc%3D (Pubitemid 46685901)
25. M Dittrich J Jurevicius M Georget F Rochais B Fleischmann J Hescheler, et al. 2001 Local response of L-type Ca(2+) current to nitric oxide in frog ventricular myocytes Journal de Physiologie 534 109 121 10.1111/j.1469-7793. 2001.00109.x 1:CAS:528:DC%2BD3MXltlejt7s%3D (Pubitemid 32631760)
26. 2+ current. Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation The Journal of Biological Chemistry 268 26286 26295 7902837 1:CAS:528: DyaK3sXmsVKhtr8%3D
27. M Rivet-Bastide G Vandecasteele S Hatem I Verde A Benardeau JJ Mercadier, et al. 1997 cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes Journal of Clinical Investigation 99 2710 2718 10.1172/JCI119460 9169501 1:CAS:528:DyaK2sXjs1Klurk%3D
28. 2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes Proceedings of the National Academy of Sciences of the United States of America 88 1197 1201 10.1073/pnas.88.4.1197 1705030 1:CAS:528: DyaK3MXhsVSgur4%3D
29. R Fischmeister L Castro A Abi-Gerges F Rochais G Vandecasteele 2005 Species- and tissue-dependent effects of NO and cyclic GMP on cardiac ion channels Comparative Biochemistry and Physiology. Part A: Molecular & Integrative Physiology 142 136 143 10.1016/j.cbpb.2005.04.012 1:CAS:528:DC%2BD2MXhtFShsr%2FE (Pubitemid 41443573)
30. M Mongillo CG Tocchetti A Terrin V Lissandron YF Cheung WR Dostmann, et al. 2006 Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway Circulation Research 98 226 234 10.1161/01.RES.0000200178.34179.93 16357307 1:CAS:528:DC%2BD28Xnt1Cqsg%3D%3D
31. LR Castro I Verde DM Cooper R Fischmeister 2006 Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes Circulation 113 2221 2228 10.1161/CIRCULATIONAHA.105.599241 16651469 1:CAS:528:DC%2BD28XktVWhtLg%3D
32. I Diebold T Djordjevic A Petry A Hatzelmann H Tenor J Hess, et al. 2009 Phosphodiesterase 2 mediates redox-sensitive endothelial cell proliferation and angiogenesis by thrombin via Rac1 and NADPH oxidase 2 Circulation Research 104 1169 1177 10.1161/CIRCRESAHA.109.196592 19390057 1:CAS:528:DC%2BD1MXlslCqu7w%3D
33. Y Shakur LS Holst TR Landstrom M Movsesian E Degerman V Manganiello 2001 Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family Progress in Nucleic Acid Research and Molecular Biology 66 241 277 10.1016/S0079-6603(00)66031-2 11051766 1:STN:280:DC%2BD3crgsVamsg%3D%3D
34. YH Choi D Ekholm J Krall F Ahmad E Degerman VC Manganiello, et al. 2001 Identification of a novel isoform of the cyclic-nucleotide phosphodiesterase PDE3A expressed in vascular smooth-muscle myocytes The Biochemical Journal 353 41 50 10.1042/0264-6021:3530041 11115397 1:CAS:528:DC%2BD3MXnslyhuw%3D%3D (Pubitemid 32094598)
35. Y Liu Y Shakur M Yoshitake Kambayashi J Ji 2001 Cilostazol (pletal): A dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake Cardiovascular Drug Reviews 19 369 386 10.1111/j.1527-3466.2001.tb00076.x 11830753 1:CAS:528:DC%2BD38XjtVCjtLo%3D
36. E Patrucco A Notte L Barberis G Selvetella A Maffei M Brancaccio, et al. 2004 PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects Cell 118 375 387 10.1016/j.cell.2004.07.017 15294162 1:CAS:528:DC%2BD2cXmslKrsL8%3D (Pubitemid 39061117)
37. P Voigt MB Dorner M Schaefer 2006 Characterization of p87PIKAP, a novel regulatory subunit of phosphoinositide 3-kinase gamma that is highly expressed in heart and interacts with PDE3B The Journal of Biological Chemistry 281 9977 9986 10.1074/jbc.M512502200 16476736 1:CAS:528:DC%2BD28Xjt1KntLg%3D (Pubitemid 43864530)
38. B Sun H Li Y Shakur J Hensley S Hockman J Kambayashi, et al. 2007 Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice Cellular Signalling 19 1765 1771 10.1016/j.cellsig.2007.03.012 17482796 1:CAS:528:DC%2BD2sXmvV2gsLo%3D (Pubitemid 46935432)
39. JR Benotti W Grossman E Braunwald DD Davolos AA Alousi 1978 Hemodynamic assessment of amrinone. A new inotropic agent The New England Journal of Medicine 299 1373 1377 10.1056/NEJM197812212992501 714115 1:STN:280: DyaE1M%2FltlWitg%3D%3D
40. DS Baim AV McDowell J Cherniles ES Monrad JA Parker J Edelson, et al. 1983 Evaluation of a new bipyridine inotropic agent-milrinone-in patients with severe congestive heart failure The New England Journal of Medicine 309 748 756 10.1056/NEJM198309293091302 6888453 1:STN:280:DyaL3s3pslGgug%3D%3D
41. R DiBianco R Shabetai W Kostuk J Moran RC Schlant R Wright 1989 A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure The New England Journal of Medicine 320 677 683 10.1056/NEJM198903163201101 2646536 1:STN:280:DyaL1M7lvFejsg%3D%3D
42. Xamoterol in severe heart failure 1990 The Xamoterol in severe heart failure study group Lancet 336 1 6 10.1016/0140-6736(90)91517-E (Pubitemid 20207866)
43. F Oliva R Latini A Politi L Staszewsky AP Maggioni E Nicolis, et al. 1999 Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial American Heart Journal 138 247 253 10.1016/S0002-8703(99) 70108-0 10426835 1:CAS:528:DyaK1MXlsFegt7k%3D (Pubitemid 29379674)
44. B Ding J Abe H Wei Q Huang RA Walsh CA Molina, et al. 2005 Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: Implication in heart failure Circulation 111 2469 2476 10.1161/01.CIR.0000165128.39715.87 15867171 1:CAS:528:DC%2BD2MXjvFOju74%3D (Pubitemid 40696135)
45. B Ding J Abe H Wei H Xu W Che T Aizawa, et al. 2005 A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis Proceedings of the National Academy of Sciences of the United States of America 102 14771 14776 10.1073/pnas.0506489102 16186489 1:CAS:528:DC%2BD2MXhtFKjsbzM (Pubitemid 41457131)
46. H Tomita M Nazmy K Kajimoto G Yehia CA Molina J Sadoshima 2003 Inducible cAMP early repressor (ICER) is a negative-feedback regulator of cardiac hypertrophy and an important mediator of cardiac myocyte apoptosis in response to beta-adrenergic receptor stimulation Circulation Research 93 12 22 10.1161/01.RES.0000079794.57578.F1 12791704 1:CAS:528:DC%2BD3sXltVGrsrk%3D (Pubitemid 36859036)
47. B Mioduszewska J Jaworski L Kaczmarek 2003 Inducible cAMP early repressor (ICER) in the nervous system-A transcriptional regulator of neuronal plasticity and programmed cell death Journal of Neurochemistry 87 1313 1320 10.1046/j.1471-4159.2003.02116.x 14713288 1:CAS:528:DC%2BD2cXit1Kk
48. J Jaworski B Mioduszewska A Sanchez-Capelo I Figiel A Habas A Gozdz, et al. 2003 Inducible cAMP early repressor, an endogenous antagonist of cAMP responsive element-binding protein, evokes neuronal apoptosis in vitro The Journal of Neuroscience 23 4519 4526 12805292 1:CAS:528:DC%2BD3sXkslOksro%3D
49. C Yan CL Miller J Abe 2007 Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart Circulation Research 100 489 501 10.1161/01.RES.0000258451.44949.d7 17332439 1:CAS:528:DC%2BD2sXitFylsbw%3D (Pubitemid 46673258)
50. M Packer JR Carver RJ Rodeheffer RJ Ivanhoe R DiBianco SM Zeldis, et al. 1991 Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group The New England Journal of Medicine 325 1468 1475 10.1056/NEJM199111213252103 1944425 1:STN:280:DyaK38%2FkvFGlsQ%3D%3D
51. C Yan B Ding T Shishido CH Woo S Itoh KI Jeon, et al. 2007 Activation of extracellular signal-regulated kinase 5 reduces cardiac apoptosis and dysfunction via inhibition of a phosphodiesterase 3A/inducible cAMP early repressor feedback loop Circulation Research 100 510 519 10.1161/01.RES. 0000259045.49371.9c 17272811 1:CAS:528:DC%2BD2sXitFyltr4%3D (Pubitemid 46673260)
52. A Abi-Gerges W Richter F Lefebvre P Mateo A Varin C Heymes, et al. 2009 Decreased expression and activity of cAMP phosphodiesterases in cardiac hypertrophy and its impact on beta-adrenergic cAMP signals Circulation Research 105 784 792 10.1161/CIRCRESAHA.109.197947 19745166 1:CAS:528:DC%2BD1MXht1Sqs77O
53. D Ma L Fu J Shen P Zhou Y Gao R Xie, et al. 2009 Interventional effect of valsartan on expression of inducible cAMP early repressor and phosphodiesterase 3A in rats after myocardial infarction European Journal of Pharmacology 602 348 354 10.1016/j.ejphar.2008.11.002 19027736 1:CAS:528:DC%2BD1MXksVajtw%3D%3D
54. SE Lehnart XH Wehrens S Reiken S Warrier AE Belevych RD Harvey, et al. 2005 Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias Cell 123 25 35 10.1016/j.cell.2005.07.030 16213210 1:CAS:528:DC%2BD2MXhtFelt7nL (Pubitemid 41414526)
55. XH Wehrens SE Lehnart F Huang JA Vest SR Reiken PJ Mohler, et al. 2003 FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death Cell 113 829 840 10.1016/S0092-8674(03)00434-3 12837242 1:CAS:528:DC%2BD3sXlsVSjtb0%3D (Pubitemid 36792028)
56. MD Houslay GS Baillie DH Maurice 2007 cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: A molecular toolbox for generating compartmentalized cAMP signaling Circulation Research 100 950 966 10.1161/01.RES.0000261934.56938.38 17431197 1:CAS:528:DC%2BD2sXjvVKjtbg%3D (Pubitemid 46598920)
57. RC Kukreja R Ockaili F Salloum C Yin J Hawkins A Das, et al. 2004 Cardioprotection with phosphodiesterase-5 inhibition-A novel preconditioning strategy Journal of Molecular and Cellular Cardiology 36 165 173 10.1016/j.yjmcc.2003.11.001 14871543 1:CAS:528:DC%2BD2cXhtVOlsLg%3D (Pubitemid 38202344)
58. DA Kass HC Champion JA Beavo 2007 Phosphodiesterase type 5: Expanding roles in cardiovascular regulation Circulation Research 101 1084 1095 10.1161/CIRCRESAHA.107.162511 18040025 1:CAS:528:DC%2BD2sXhtlahurjJ (Pubitemid 350146434)
59. F Salloum C Yin L Xi RC Kukreja 2003 Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart Circulation Research 92 595 597 10.1161/01.RES.0000066853.09821.98 12637371 1:CAS:528:DC%2BD3sXitlKntrc%3D (Pubitemid 36417692)
60. A Das L Xi RC Kukreja 2005 Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling The Journal of Biological Chemistry 280 12944 12955 10.1074/jbc.M404706200 15668244 1:CAS:528:DC%2BD2MXislygsLc%3D
61. PW Fisher F Salloum A Das H Hyder RC Kukreja 2005 Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity Circulation 111 1601 1610 10.1161/01.CIR.0000160359.49478.C2 15811867 1:CAS:528:DC%2BD2MXislahtbY%3D (Pubitemid 40525159)
62. R Ockaili F Salloum J Hawkins RC Kukreja 2002 Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits American Journal of Physiology. Heart and Circulatory Physiology 283 H1263 1269 12181158 1:CAS:528:DC%2BD38XntFOnsrw%3D
63. E Takimoto N Koitabashi S Hsu EA Ketner M Zhang T Nagayama, et al. 2009 Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice Journal of Clinical Investigation 119 408 420 19127022 1:CAS:528:DC%2BD1MXhslegs7w%3D
64. J Corbin S Rannels D Neal P Chang K Grimes A Beasley, et al. 2003 Sildenafil citrate does not affect cardiac contractility in human or dog heart Current Medical Research and Opinion 19 747 752 10.1185/030079903125002522 14687446 1:CAS:528:DC%2BD3sXhtVSjtr7I (Pubitemid 37466145)
65. F Vandeput J Krall R Ockaili FN Salloum V Florio JD Corbin, et al. 2009 cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium The Journal of Pharmacology and Experimental Therapeutics 330 884 891 10.1124/jpet.109.154468 19546307 1:CAS:528: DC%2BD1MXhtVyitL3N
66. M Zhang N Koitabashi T Nagayama R Rambaran N Feng E Takimoto, et al. 2008 Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes Cellular Signalling 20 2231 2236 10.1016/j.cellsig.2008.08.012 18790048 1:CAS:528:DC%2BD1cXhtlCru7vL
67. RT Schermuly C Inholte HA Ghofrani H Gall N Weissmann A Weidenbach, et al. 2005 Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: Amplification by different type phosphodiesterase inhibitors Respiratory Research 6 76 10.1186/1465-9921-6-76 16033645 1:CAS:528:DC%2BD2MXhtVahsrnF (Pubitemid 41417583)
68. GA Paul JS Gibbs AR Boobis A Abbas MR Wilkins 2005 Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension British Journal of Clinical Pharmacology 60 107 112 10.1111/j.1365-2125.2005. 02383.x 15963102 1:CAS:528:DC%2BD2MXmvF2ktrc%3D (Pubitemid 40942789)
69. BA Borlaug V Melenovsky T Marhin P Fitzgerald DA Kass 2005 Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans Circulation 112 2642 2649 10.1161/CIRCULATIONAHA.105.540500 16246964 1:CAS:528: DC%2BD2MXhtFajtLrL (Pubitemid 41532601)
70. E Takimoto HC Champion M Li D Belardi S Ren ER Rodriguez, et al. 2005 Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy Natural Medicines 11 214 222 10.1038/nm1175 1:CAS:528:DC%2BD2MXpvF2nug%3D%3D (Pubitemid 40321358)
71. FN Salloum VQ Chau NN Hoke A Abbate A Varma RA Ockaili, et al. 2009 Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein-kinase G-dependent generation of hydrogen sulfide Circulation 120 S31 S36 10.1161/CIRCULATIONAHA.108.843979 19752383 1:CAS:528:DC%2BD1MXhtFWhur3J
72. P Pokreisz S Vandenwijngaert V Bito A Van den Bergh I Lenaerts C Busch, et al. 2009 Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice Circulation 119 408 416 10.1161/ CIRCULATIONAHA.108.822072 19139381 1:CAS:528:DC%2BD1MXpt1Cmsw%3D%3D
73. J Nagendran SL Archer D Soliman V Gurtu R Moudgil A Haromy, et al. 2007 Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility Circulation 116 238 248 10.1161/CIRCULATIONAHA.106.655266 17606845 1:CAS:528:DC%2BD2sXnsVyjsr0%3D (Pubitemid 47196559)
74. JH Traverse YJ Chen R Du RJ Bache 2000 Cyclic nucleotide phosphodiesterase type 5 activity limits blood flow to hypoperfused myocardium during exercise Circulation 102 2997 3002 11113052 1:CAS:528: DC%2BD3MXitlWmsg%3D%3D
75. G Jackson 2001 Phosphodiesterase 5 inhibition: Effects on the coronary vasculature International Journal of Clinical Practice 55 183 188 11351772 1:CAS:528:DC%2BD3MXjvVamuro%3D
76. RG Brindis RA Kloner 2003 Sildenafil in patients with cardiovascular disease The American Journal of Cardiology 92 26M 36M 10.1016/S0002-9149(02) 03368-4 14609621 1:CAS:528:DC%2BD3sXhtVSrurfL (Pubitemid 37386273)
77. M Sahara M Sata T Morita T Nakajima Y Hirata R Nagai 2010 A phosphodiesterase-5 inhibitor vardenafil enhances angiogenesis through a protein kinase G-dependent hypoxia-inducible factor-1/vascular endothelial growth factor pathway Arteriosclerosis, Thrombosis, and Vascular Biology 30 1315 1324 10.1161/ATVBAHA.109.201327 20413734 1:CAS:528:DC%2BC3cXnsFGgtL8%3D
78. A Pyriochou Z Zhou V Koika C Petrou P Cordopatis WC Sessa, et al. 2007 The phosphodiesterase 5 inhibitor sildenafil stimulates angiogenesis through a protein kinase G/MAPK pathway Journal of Cellular Physiology 211 197 204 10.1002/jcp.20929 17226792 1:CAS:528:DC%2BD2sXis12jtb8%3D (Pubitemid 46363910)
79. SH Soderling SJ Bayuga JA Beavo 1998 Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase Proceedings of the National Academy of Sciences of the United States of America 95 8991 8996 10.1073/pnas.95.15.8991 9671792 1:CAS:528:DyaK1cXkvFaltbw%3D (Pubitemid 28350602)
80. FN Salloum A Abbate A Das JE Houser CA Mudrick IZ Qureshi, et al. 2008 Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice American Journal of Physiology. Heart and Circulatory Physiology 294 H1398 1406 10.1152/ajpheart.91438.2007 18223185 1:CAS:528:DC%2BD1cXjsFymt7Y%3D (Pubitemid 351468739)
81. F Rochais A Abi-Gerges K Horner F Lefebvre DM Cooper M Conti, et al. 2006 A specific pattern of phosphodiesterases controls the cAMP signals generated by different Gs-coupled receptors in adult rat ventricular myocytes Circulation Research 98 1081 1088 10.1161/01.RES.0000218493.09370.8e 16556871 1:CAS:528:DC%2BD28Xjs1Kltro%3D
82. 2+ current in rat ventricular myocytes British Journal of Pharmacology 127 65 74 10.1038/sj.bjp.0702506 10369457 1:CAS:528:DyaK1MXjtVGlsbg%3D (Pubitemid 29213233)
83. G Vandecasteele I Verde C Rucker-Martin P Donzeau-Gouge R Fischmeister 2001 Cyclic GMP regulation of the L-type Ca(2+) channel current in human atrial myocytes Journal de Physiologie 533 329 340 10.1111/j.1469-7793.2001.0329a.x 1:CAS:528:DC%2BD3MXltVSktLs%3D (Pubitemid 32519991)
84. CO Malecot DM Bers BG Katzung 1986 Biphasic contractions induced by milrinone at low temperature in ferret ventricular muscle: Role of the sarcoplasmic reticulum and transmembrane calcium influx Circulation Research 59 151 162 2427247 1:CAS:528:DyaL2sXktlOjsg%3D%3D
85. M Yano M Kohno T Ohkusa M Mochizuki J Yamada T Hisaoka, et al. 2000 Effect of milrinone on left ventricular relaxation and Ca(2+) uptake function of cardiac sarcoplasmic reticulum American Journal of Physiology. Heart and Circulatory Physiology 279 H1898 1905 11009478 1:CAS:528:DC%2BD3cXns1egsL8%3D
86. GS Baillie A Sood I McPhee I Gall SJ Perry RJ Lefkowitz, et al. 2003 beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi Proceedings of the National Academy of Sciences of the United States of America 100 940 945 10.1073/pnas.262787199 12552097 1:CAS:528:DC%2BD3sXhtF2gsLw%3D (Pubitemid 36183934)
87. A Das R Ockaili F Salloum RC Kukreja 2004 Protein kinase C plays an essential role in sildenafil-induced cardioprotection in rabbits American Journal of Physiology. Heart and Circulatory Physiology 286 H1455 1460 10.1152/ajpheart.01040.2003 15020304 1:CAS:528:DC%2BD2cXjtlKku70%3D (Pubitemid 38381155)
88. H Senzaki CJ Smith GJ Juang T Isoda SP Mayer A Ohler, et al. 2001 Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure The FASEB Journal 15 1718 1726 10.1096/fj.00-0538com 11481219 1:CAS:528:DC%2BD3MXmsFehsL4%3D (Pubitemid 32730219)